TISIDB

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus outer membrane Single-pass type IV membrane protein Cytoplasmic side Nucleus Chromosome, telomere Note=Localized exclusively at telomeres from the leptotene to diplotene stages. Colocalizes with SUN2 at sites of telomere attachment in meiocytes. At oocyte MI stage localized around the spindle, at MII stage localized to the spindle poles.
Domain	PF14662 Coiled-coil region of CCDC155 or KASH
Function	As a component of the LINC (LInker of Nucleoskeleton and Cytoskeleton) complex, involved in the connection between the nuclear lamina and the cytoskeleton. The nucleocytoplasmic interactions established by the LINC complex play an important role in the transmission of mechanical forces across the nuclear envelope and in nuclear movement and positioning. Required for telomere attachment to nuclear envelope in the prophase of meiosis and for rapid telomere prophase movements implicating a SUN1/2:KASH5 LINC complex in which SUN1 and SUN2 seem to act at least partial redundantly. Required for homologue pairing during meiotic prophase in spermatocytes and probably oocytes. Essential for male and female gametogenesis. Recruits cytoplasmic dynein to telomere attachment sites at the nuclear envelope in spermatocytes. In oocytes is involved in meiotic resumption and spindle formation.

> Gene Ontology [ TOP ]
Biological Process	GO:0000226 microtubule cytoskeleton organization GO:0000724 double-strand break repair via homologous recombination GO:0000725 recombinational repair GO:0006302 double-strand break repair GO:0006310 DNA recombination GO:0007015 actin filament organization GO:0007051 spindle organization GO:0007059 chromosome segregation GO:0007126 meiotic nuclear division GO:0007127 meiosis I GO:0007129 synapsis GO:0007281 germ cell development GO:0007283 spermatogenesis GO:0007292 female gamete generation GO:0022412 cellular process involved in reproduction in multicellular organism GO:0034397 telomere localization GO:0045132 meiotic chromosome segregation GO:0045143 homologous chromosome segregation GO:0048232 male gamete generation GO:0048477 oogenesis GO:0050000 chromosome localization GO:0051225 spindle assembly GO:0051303 establishment of chromosome localization GO:0051321 meiotic cell cycle GO:0051640 organelle localization GO:0051653 spindle localization GO:0051656 establishment of organelle localization GO:0070192 chromosome organization involved in meiotic cell cycle GO:0090220 chromosome localization to nuclear envelope involved in homologous chromosome segregation GO:0098813 nuclear chromosome segregation GO:1903046 meiotic cell cycle process
Molecular Function	GO:0070840 dynein complex binding
Cellular Component	GO:0000781 chromosome, telomeric region GO:0000793 condensed chromosome GO:0000794 condensed nuclear chromosome GO:0000795 synaptonemal complex GO:0000800 lateral element GO:0000922 spindle pole GO:0005635 nuclear envelope GO:0005640 nuclear outer membrane GO:0005819 spindle GO:0019867 outer membrane GO:0031965 nuclear membrane GO:0031968 organelle outer membrane GO:0034992 microtubule organizing center attachment site GO:0034993 LINC complex GO:0044454 nuclear chromosome part GO:0072687 meiotic spindle GO:0090619 meiotic spindle pole GO:0098687 chromosomal region

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	-

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CCDC155 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CCDC155 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.56; FDR: 0.02000	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CCDC155 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.17	0.402
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.051	0.918
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.331	0.383
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.009	0.986
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.005	0.996
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.026	0.985
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	-0.335	0.605
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.017	0.99
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	-0.738	0.614
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.271	0.288

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CCDC155 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	0	2.7	-2.7	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	0	3.4	-3.4	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	12.5	0	12.5	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	9.1	-9.1	0.458
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	12.5	-1.4	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	14.3	10.7	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	3.7	1.6	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	7.1	-0.9	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CCDC155. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CCDC155. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CCDC155. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CCDC155. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CCDC155 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CCDC155 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CCDC155
Name	coiled-coil domain containing 155
Aliases	FLJ32658; KASH5; KASH domain-containing protein 5; Coiled-coil domain-containing protein 155; Protein KASH5
Chromosomal Location	19q13.33
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CCDC155 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CCDC155